Plasma urea cycle metabolite levels and the risk of moyamoya disease

Frontiers in Neuroscience

Neuroscience

Xiaofan Yu¹  Wei Liu¹  Xingju Liu¹  Qian Zhang¹  Rong Wang¹  Yan Zhang¹  Yuanren Zhai¹  Xun Ye¹  Peicong Ge¹  Dong Zhang²  Jizong Zhao³ 

[1] Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China;China National Clinical Research Center for Neurological Diseases, Beijing, China;Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China;Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China;Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, China;Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China;China National Clinical Research Center for Neurological Diseases, Beijing, China;Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China;Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China;Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, China;Department of Neurosurgery, Beijing Hospital, Beijing, China;Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China;China National Clinical Research Center for Neurological Diseases, Beijing, China;Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China;Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China;Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, China;Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China;

关键词: moyamoya disease;    urea cycle;    ornithine;    arginine;    risk factors;   

DOI  :  10.3389/fnins.2023.1163733

 received in 2023-02-11, accepted in 2023-06-21,  发布年份 2023

来源: Frontiers

【 摘 要 】

Background and purposeUrea cycle metabolites are expected to be the biomarkers for cerebrovascular diseases. However, the effects of circulating urea cycle metabolites on the risk of MMD and its subcategories remain unclear. The aim of this study was to prospectively investigate the association between plasma urea cycle metabolites and the risk of MMD and its subcategories.MethodsWe measured plasma urea cycle metabolite levels for 360 adult MMD patients and 89 matched healthy controls. Clinical and laboratory characteristics were obtained from the medical record. The study was conducted from July 2020 to December 2021.ResultsAfter multivariate adjustment, the risk of MMD increased with each increment in ornithine level (per natural log [ornithine] increment: OR, 3.893; 95% CI, 1.366–11.090). The risk of MMD decreased with each increment in arginine level (per natural log [arginine] increment: OR, 0.109; 95% CI, 0.028–0.427), urea level (per natural log [urea] increment: OR, 0.261; 95% CI, 0.072–0.940), and global arginine bioavailability ratio (GABR) level (per natural log [GABR] increment: OR, 0.189; 95% CI, 0.074–0.484). The addition of plasma arginine (integrated discrimination improvement: 1.76%, p = 0.021) or GABR (integrated discrimination improvement: 1.76%, p = 0.004) to conventional risk factors significantly improved the risk reclassification for MMD.ConclusionPlasma ornithine levels are positively associated with the risk of MMD. By contrast, the levels of arginine, urea, and GABR are inversely related to the risk of MMD. Plasma urea cycle metabolites might be potential biomarkers for the risk of MMD.

【 授权许可】

Unknown   
Copyright © 2023 Yu, Ge, Zhai, Liu, Zhang, Ye, Liu, Wang, Zhang, Zhao and Zhang.